✦ LIBER ✦

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction

✍ Scribed by Jay H. Traverse; Timothy D. Henry; Douglas E. Vaughn; Stephen G. Ellis; Carl J. Pepine; James T. Willerson; David X.M. Zhao; Linda B. Piller; Marc S. Penn; Barry J. Byrne; Emerson C. Perin; Adrian P. Gee; Antonis K. Hatzopoulos; David H. McKenna; John R. Forder; Doris A. Taylor; Christopher R. Cogle; Rachel E. Olson; Beth C. Jorgenson; Shelly L. Sayre; Rachel W. Vojvodic; David J. Gordon; Sonia I. Skarlatos; Lemuel A. Moye'; Robert D. Simari

Book ID: 116191818
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 158 KB
Volume: 158
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2009.06.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and rationale for the Myocardial

Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: A multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction

✍ Noémi Nyolczas; Mariann Gyöngyösi; Gilbert Beran; Markus Dettke; Senta Graf; Hei 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Rationale and design of the Transendocar

Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy

✍ Barry Trachtenberg; Darcy L. Velazquez; Adam R. Williams; Ian McNiece; Joel Fish 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 322 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB